Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic

Immune checkpoint inhibitors (ICPIs) have revolutionized the management and prognosis of fit patients with advanced non-small cell lung cancer (NSCLC). Recently, the publication of 5-year survival rates has cemented the role of ICPIs in NSCLC. An ongoing challenge is to determine the optimal treatme...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Alex Friedlaender, Chul Kim, Alfredo Addeo
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2020-05-01
Serija:	Frontiers in Oncology
Teme:	NSCLC COVID19 immune checkpoint inhibitors duration first line
Online dostop:	https://www.frontiersin.org/article/10.3389/fonc.2020.00862/full
Oznake:	Označite Brez oznak, prvi označite!